FindTrial
Sign In

ORAL METHOTREXATE AND ORAL BETAMETHASONE MINI PULSE IN LICHEN PLANUS

EFFICACY AND SAFETY OF ORAL METHOTREXATE AND ORAL BETAMETHASONE MINI PULSE IN THE TREATMENT OF LICHEN PLANUS : A RANDOMISED CONTROL STUDY - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/06/088150
Enrollment
60
Registered
2025-06-03
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L439- Lichen planus, unspecified

Interventions

Intervention1: Oral methotrexate: oral methotrexate at a dose of 15mg once weekly and folic acid supplementation 4 days a week Control Intervention1: oral betamethasone mini pulse: oral betamethasone

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All patients giving consent aged between 18-45 years of age. 2. patients with lichen planus having a treatment free period of 2 months.

Exclusion criteria

Exclusion criteria: 1. active bacterial, viral, mycobacterial, fungal infections or history of malignancies 2. alcoholics and patients with alcoholic liver disease, liver cirrhosis, fibrosis, chronic liver disease. 3.Anemia, neutropenia, lymphopenia. 4. diabetes, hyperlipidaemia, hypertension, renal disease, epilepsy, glaucoma. 5. patients receiving concomitant radiotherapy. 6. pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
lichen planus activity and damage indexTimepoint: 4 weeks, 8 weeks and 12 weeks—

Secondary

MeasureTime frame
NILTimepoint:—

Countries

India

Contacts

Public ContactDr.Moparty pavani aiswarya

kalinga institute of medical sciences

laxman.derm@gmail.com9500282040

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026